Unprecedented Therapeutic Potential with a Combination of A2A/NR2B Receptor Antagonists As Observed in the 6-OHDA Lesioned Rat Model of Parkinson's Disease

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Dec 17

PMID 25513815

Citations 10

Authors

Anne Michel

Patrick Downey

Jean-Marie Nicolas

Dieter Scheller

Affiliations

Soon will be listed here.

Abstract

In Parkinson's disease, the long-term use of dopamine replacing agents is associated with the development of motor complications; therefore, there is a need for non-dopaminergic drugs. This study evaluated the potential therapeutic impact of six different NR2B and A2A receptor antagonists given either alone or in combination in unilateral 6-OHDA-lesioned rats without (monotherapy) or with (add-on therapy) the co-administration of L-Dopa: Sch-58261+ Merck 22; Sch-58261+Co-101244; Preladenant + Merck 22; Preladenant + Radiprodil; Tozadenant + Radiprodil; Istradefylline + Co-101244. Animals given monotherapy were assessed on distance traveled and rearing, whereas those given add-on therapy were assessed on contralateral rotations. Three-way mixed ANOVA were conducted to assess the main effect of each drug separately and to determine whether any interaction between two drugs was additive or synergistic. Additional post hoc analyses were conducted to compare the effect of the combination with the effect of the drugs alone. Motor activity improved significantly and was sustained for longer when the drugs were given in combination than when administered separately at the same dose. Similarly, when tested as add-on treatment to L-Dopa, the combinations resulted in higher levels of contralateral rotation in comparison to the single drugs. Of special interest, the activity observed with some combinations could not be described by a simplistic additive effect and involved more subtle synergistic pharmacological interactions. The combined administration of A2A/NR2B-receptor antagonists improved motor behaviour in 6-OHDA rats. Given the proven translatability of this model such a combination may be expected to be effective in improving motor symptoms in patients.

Citing Articles

Radiosynthesis and In Vitro Evaluation of [C]tozadenant as Adenosine A Receptor Radioligand.

Humpert S, Schneider D, Lang M, Schulze A, Neumaier F, Holschbach M Molecules. 2024; 29(5).

PMID: 38474602 PMC: 10935082. DOI: 10.3390/molecules29051089.

Dimethyl Fumarate Exerts a Neuroprotective Effect by Enhancing Mitophagy via the NRF2/BNIP3/PINK1 Axis in the MPP Iodide-Induced Parkinson's Disease Mice Model.

Pinjala P, Tryphena K, Kulkarni A, Goswami P, Khatri D J Alzheimers Dis Rep. 2024; 8(1):329-344.

PMID: 38405353 PMC: 10894611. DOI: 10.3233/ADR-230128.

In vitro and in vivo activity of a novel oxamide-hydrazone hybrid derivative against triple-negative breast cancer.

Tahmasvand R, Dehghani S, Kooshafar Z, Emami Najafi S, Almasirad A, Salimi M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):5119-5129.

PMID: 38240779 DOI: 10.1007/s00210-023-02931-6.

A Glutamate -Methyl-d-Aspartate (NMDA) Receptor Subunit 2B-Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use.

Myers S, Ruppa K, Wilson L, Tahirovic Y, Lyuboslavsky P, Menaldino D J Pharmacol Exp Ther. 2021; 379(1):41-52.

PMID: 34493631 PMC: 8626636. DOI: 10.1124/jpet.120.000370.

Metal Chelation Therapy and Parkinson's Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs.

Tosato M, Di Marco V Biomolecules. 2019; 9(7).

PMID: 31324037 PMC: 6681387. DOI: 10.3390/biom9070269.

References

Nash J, Brotchie J . A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J Neurosci. 2000; 20(20):7782-9. PMC: 6772864. View

Layton M, Kelly 3rd M, Rodzinak K, Sanderson P, Young S, Bednar R . Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists. ACS Chem Neurosci. 2012; 2(7):352-62. PMC: 3369735. DOI: 10.1021/cn200013d. View

Duty S . Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease. CNS Drugs. 2012; 26(12):1017-32. DOI: 10.1007/s40263-012-0016-z. View

Kelsey J, Mague S, Pijanowski R, Harris R, Kleckner N, Matthews R . NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats. Psychopharmacology (Berl). 2004; 175(2):179-88. DOI: 10.1007/s00213-004-1799-5. View

Schwarting R, Huston J . The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol. 1996; 50(2-3):275-331. DOI: 10.1016/s0301-0082(96)00040-8. View

Steece-Collier K, Chambers L, Menniti F, Greenamyre J . Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol. 2000; 163(1):239-43. DOI: 10.1006/exnr.2000.7374. View

Nash J, Ravenscroft P, McGuire S, Crossman A, Menniti F, Brotchie J . The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol. 2004; 188(2):471-9. DOI: 10.1016/j.expneurol.2004.05.004. View

Marino M, Valenti O, Conn P . Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging. 2003; 20(5):377-97. DOI: 10.2165/00002512-200320050-00006. View

Addy C, Assaid C, Hreniuk D, Stroh M, Xu Y, Herring W . Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. J Clin Pharmacol. 2009; 49(7):856-64. DOI: 10.1177/0091270009336735. View

10.

Rao N, Dvorchik B, SUSSMAN N, Wang H, Yamamoto K, Mori A . A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin. J Clin Pharmacol. 2008; 48(9):1092-8. DOI: 10.1177/0091270008320924. View

11.

Mihara T, Mihara K, Yarimizu J, Mitani Y, Matsuda R, Yamamoto H . Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. J Pharmacol Exp Ther. 2007; 323(2):708-19. DOI: 10.1124/jpet.107.121962. View

12.

Hauber W, Munkle M . The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol. 1996; 354(2):179-86. DOI: 10.1007/BF00178718. View

13.

Delfino M, Stefano A, Ferrario J, Taravini I, Murer M, Gershanik O . Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behav Brain Res. 2004; 152(2):297-306. DOI: 10.1016/j.bbr.2003.10.009. View

14.

Hodgson R, Bertorelli R, Varty G, Lachowicz J, Forlani A, Fredduzzi S . Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of.... J Pharmacol Exp Ther. 2009; 330(1):294-303. DOI: 10.1124/jpet.108.149617. View

15.

Loschmann P, de Groote C, Smith L, Wullner U, Fischer G, Kemp J . Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol. 2004; 187(1):86-93. DOI: 10.1016/j.expneurol.2004.01.018. View

16.

Mignon L, Wolf W . Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease. Psychopharmacology (Berl). 2007; 192(1):49-59. DOI: 10.1007/s00213-006-0680-0. View

17.

Shook B, Rassnick S, Osborne M, Davis S, Westover L, Boulet J . In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease. J Med Chem. 2010; 53(22):8104-15. DOI: 10.1021/jm100971t. View

18.

Jenner P . Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008; 9(9):665-77. DOI: 10.1038/nrn2471. View

19.

Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P . Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol. 2007; 566(1-3):94-102. DOI: 10.1016/j.ejphar.2007.03.021. View

20.

Chen B, Roche K . Regulation of NMDA receptors by phosphorylation. Neuropharmacology. 2007; 53(3):362-8. PMC: 2001266. DOI: 10.1016/j.neuropharm.2007.05.018. View